BACKGROUND & AIMS: Cancer and oncological therapy are associated with a progressive physical deterioration, malnutrition, and enhanced inflammatory burden. Our considerable data showing the strong anabolic potential of amino acids (AA) led us to test whether AA can acutely stimulate muscle protein synthesis in cancer patients (CA) undergoing intense chemotherapy. METHODS: Mixed muscle fractional synthesis rate (FSR), rates of phenylalanine appearance and disappearance (Ra and Rd), and net phenylalanine balance (NB) were measured during a primed constant infusion of L-[ring-(2)H(5)]phenylalanine. Blood and muscle tissue samples were collected in the basal state and following ingestion of 40 g of AA given in 30 mL boluses every 10 min for 3h. Serum and tissue cytokines and NF-kappaB expression in skeletal muscle were measured and compared to normative, healthy older controls (OC). RESULTS: Skeletal muscle TNF-alpha, IL-6, and NF-kappaB were elevated in CA. FSR and model-derived protein synthesis (Rd) increased significantly from basal to AA (FSR: 0.052+/-0.009 vs. 0.120+/-0.008%h(-1), P<0.001; Rd: 23.1+/-4.1 vs. 36.4+/-5.0 nmol min(-1) 100 mL leg(-1), P0.05). Model-derived protein breakdown (Ra) remained unchanged from basal to AA. Phenylalanine NB improved from a negative basal value (-16+/-2) to zero (0.8+/-6 nmol min(-1) 100 ml leg(-1), P0.05) following AA. CONCLUSION: Despite advanced cancer, ongoing therapy, and an enhanced inflammatory burden, AA were capable of acutely stimulating muscle protein synthesis in these patients.
BACKGROUND & AIMS:Cancer and oncological therapy are associated with a progressive physical deterioration, malnutrition, and enhanced inflammatory burden. Our considerable data showing the strong anabolic potential of amino acids (AA) led us to test whether AA can acutely stimulate muscle protein synthesis in cancerpatients (CA) undergoing intense chemotherapy. METHODS: Mixed muscle fractional synthesis rate (FSR), rates of phenylalanine appearance and disappearance (Ra and Rd), and net phenylalanine balance (NB) were measured during a primed constant infusion of L-[ring-(2)H(5)]phenylalanine. Blood and muscle tissue samples were collected in the basal state and following ingestion of 40 g of AA given in 30 mL boluses every 10 min for 3h. Serum and tissue cytokines and NF-kappaB expression in skeletal muscle were measured and compared to normative, healthy older controls (OC). RESULTS: Skeletal muscle TNF-alpha, IL-6, and NF-kappaB were elevated in CA. FSR and model-derived protein synthesis (Rd) increased significantly from basal to AA (FSR: 0.052+/-0.009 vs. 0.120+/-0.008%h(-1), P<0.001; Rd: 23.1+/-4.1 vs. 36.4+/-5.0 nmol min(-1) 100 mL leg(-1), P0.05). Model-derived protein breakdown (Ra) remained unchanged from basal to AA. Phenylalanine NB improved from a negative basal value (-16+/-2) to zero (0.8+/-6 nmol min(-1) 100 ml leg(-1), P0.05) following AA. CONCLUSION: Despite advanced cancer, ongoing therapy, and an enhanced inflammatory burden, AA were capable of acutely stimulating muscle protein synthesis in these patients.
Authors: Arny A Ferrando; Melinda Sheffield-Moore; Catherine W Yeckel; Charles Gilkison; Jie Jiang; Alison Achacosa; Steven A Lieberman; Kevin Tipton; Robert R Wolfe; Randall J Urban Journal: Am J Physiol Endocrinol Metab Date: 2002-03 Impact factor: 4.310
Authors: M Sheffield-Moore; C W Yeckel; E Volpi; S E Wolf; B Morio; D L Chinkes; D Paddon-Jones; R R Wolfe Journal: Am J Physiol Endocrinol Metab Date: 2004-05-18 Impact factor: 4.310
Authors: Douglas Paddon-Jones; Melinda Sheffield-Moore; Xiao-Jun Zhang; Elena Volpi; Steven E Wolf; Asle Aarsland; Arny A Ferrando; Robert R Wolfe Journal: Am J Physiol Endocrinol Metab Date: 2003-10-28 Impact factor: 4.310
Authors: Melinda Sheffield-Moore; John E Wiktorowicz; Kizhake V Soman; Christopher P Danesi; Michael P Kinsky; Edgar L Dillon; Kathleen M Randolph; Shannon L Casperson; Dennis C Gore; Astrid M Horstman; James P Lynch; Barbara M Doucet; Joni A Mettler; Jeffrey W Ryder; Lori L Ploutz-Snyder; Jean W Hsu; Farook Jahoor; Kristofer Jennings; Gregory R White; Susan D McCammon; William J Durham Journal: Clin Transl Sci Date: 2013-10-29 Impact factor: 4.689
Authors: Nicolaas E P Deutz; Ahmed Safar; Scott Schutzler; Robert Memelink; Arny Ferrando; Horace Spencer; Ardy van Helvoort; Robert R Wolfe Journal: Clin Nutr Date: 2011-06-16 Impact factor: 7.324
Authors: Federico Bozzetti; Luigi Mariani; Salvatore Lo Vullo; Maria Luisa Amerio; Roberto Biffi; Giovanni Caccialanza; Giorgio Capuano; Giovanni Capuano; Isabel Correja; Luca Cozzaglio; Angelo Di Leo; Leonardo Di Cosmo; Concetta Finocchiaro; Cecilia Gavazzi; Antonello Giannoni; Patrizia Magnanini; Giovanni Mantovani; Manuela Pellegrini; Lidia Rovera; Giancarlo Sandri; Marco Tinivella; Enrico Vigevani Journal: Support Care Cancer Date: 2012-08 Impact factor: 3.603
Authors: Edgar L Dillon; Gurjot Basra; Astrid M Horstman; Shanon L Casperson; Kathleen M Randolph; William J Durham; Randall J Urban; Concepcion Diaz-Arrastia; Lyuba Levine; Sandra S Hatch; Maurice Willis; Gwyn Richardson; Melinda Sheffield-Moore Journal: J Cachexia Sarcopenia Muscle Date: 2012-05-15 Impact factor: 12.910